A significant increase in the FLT3-ITD allelic ratio in relapsed AML indicates that a FLT3-ITD-mutated subclone present at diagnosis may possess a growth advantage and, through clonal expansion, become the dominant clone at relapse. The gene discussed is FLT3; the disease is acute myeloid leukemia.